Announcements Trials
Browse Landscape

Status

Active not recruiting 6Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 665Neoplasms 585Colorectal Neoplasms 291Carcinoma, Non-Small-Cell Lung 289Prostatic Neoplasms 277Lung Neoplasms 217Melanoma 159Multiple Myeloma 149Neoplasm Metastasis 145Head and Neck Neoplasms 143Pancreatic Neoplasms 139Ovarian Neoplasms 129Carcinoma, Hepatocellular 126Leukemia, Myeloid, Acute 121Brain Neoplasms 111Squamous Cell Carcinoma of Head and Neck 109Colonic Neoplasms 109Uterine Cervical Neoplasms 106Stomach Neoplasms 102Recurrence 101Lymphoma 100Glioblastoma 90Lymphoma, Non-Hodgkin 82Precursor Cell Lymphoblastic Leukemia-Lymphoma 78Hematologic Neoplasms 78Lymphoma, Follicular 77Urinary Bladder Neoplasms 76Parkinson Disease 4, Autosomal Dominant Lewy Body 74Glioma 72Sarcoma 70

Interventions

avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Urothelial Cancer × 1 year × Clear all
NCT07207928 2026-01-09

AvePem

Azienda Ospedaliera Universitaria Integrata Verona

Completed
35 enrolled
Genitourinary

Urothelial Cancer

NCT05366725 2025-12-02

A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Completed
106 enrolled 36 charts
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡